SAR156597
Total Payments
$248,133
Transactions
421
Doctors
13
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $69,932 | 17 | 2 |
| 2018 | $18,652 | 45 | 3 |
| 2017 | $159,549 | 359 | 13 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $140,056 | 379 | 56.4% |
| Consulting Fee | $58,852 | 17 | 23.7% |
| Travel and Lodging | $48,228 | 17 | 19.4% |
| Food and Beverage | $996.39 | 8 | 0.4% |
Payments by Type
Research
$140,056
379 transactions
General
$108,076
42 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study | SANOFI US SERVICES INC. | $89,444 | 7 |
| Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis (IPF): A Randomized, Double-blind, Placebo-controlled, 52-week Dose-ranging Study | SANOFI US SERVICES INC. | $44,920 | 0 |
| Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study | GENZYME CORPORATION | $1,598 | 1 |
| A prospective, longitudinal, non-pharmacological, case-controlled study to,evaluate longitudinal disease behavior and biomarker data over a 52-week period,in idiopathic pulmonary fibrosis patients, | SANOFI US SERVICES INC. | $906.53 | 1 |
| A prospective, longitudinal, non-pharmacological, case-controlled study to,evaluate longitudinal disease behavior and biomarker data over a 52-week period,in idiopathic pulmonary fibrosis patients | SANOFI US SERVICES INC. | $319.60 | 1 |
| Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study | SANOFI-AVENTIS U.S. LLC | $70.00 | 1 |
Top Doctors Receiving Payments for SAR156597
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Philadelphia, PA | $130,795 | 322 |
| , MD | Pulmonary Disease | Seattle, WA | $24,435 | 9 |
| , M.D | Critical Care Medicine | New York, NY | $20,379 | 5 |
| , MD | Internal Medicine | Ann Arbor, MI | $18,352 | 7 |
| , MD | Pulmonary Disease | Burr Ridge, IL | $17,600 | 7 |
| , MD | Critical Care Medicine | New Haven, CT | $13,866 | 5 |
| , M.D | Internal Medicine | Ann Arbor, MI | $9,376 | 14 |
| , M.D., MHS | Rheumatology | Baltimore, MD | $7,829 | 9 |
| Virginia Steen | Allergy & Immunology | Washington, DC | $1,351 | 9 |
| , MD | Internal Medicine | Ann Arbor, MI | $1,060 | 9 |
| , MD | Rheumatology | Cleveland, OH | $1,036 | 9 |
| , M.D | Internal Medicine | Baltimore, MD | $1,024 | 8 |
| , M.D | Internal Medicine | Baltimore, MD | $955.51 | 6 |
| , M.D | Internal Medicine | Houston, TX | $74.54 | 2 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $138,388
- GENZYME CORPORATION $95,004
- SANOFI-AVENTIS U.S. LLC $14,740
Product Information
- Type Drug
- Total Payments $248,133
- Total Doctors 13
- Transactions 421
About SAR156597
SAR156597 is a drug associated with $248,133 in payments to 13 healthcare providers, recorded across 421 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2017 to 2019. In 2019, $69,932 was paid across 17 transactions to 2 doctors.
The most common payment nature for SAR156597 is "Unspecified" ($140,056, 56.4% of total).
SAR156597 is associated with 6 research studies, including "Efficacy and Safety of SAR156597 in the Treatment of Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-blind, Placebo-controlled, 24-week, Proof of Concept Study" ($89,444).